BRAF and melanoma: This sets the stage for large‐scale pre‐clinical evaluation of drugs such as BET bromodomain inhibitors as a means of blocking drug adaptation and increasing cell killing by MAPK inhibitors in a subset of BRAF‐mutant melanomas.